Sirius XM (SIRI) and Merck (MRK) released their latest earnings reports before opening bell this morning. Sirius XM reported $1.3 billion in revenue, which was in line with the consensus estimate. The satellite radio provider reported earnings of 4 cents per share, which was in line with consensus. In the same quarter a year ago, the company reported 3 cents per share on $1.2 billion in revenue.

Merck reported adjusted earnings of 89 cents per share, which was in line with the consensus estimate, on $10.12 billion in revenue, compared to the consensus of $10.23 billion. In the same quarter a year ago, the drug maker reported revenue of $10.22 billion.

Sirius XM beats estimate for subscriber adds

Sirius XM added $1.75 million subscribers last year, coming out head of the consensus of 1.65 million. The company had more than 31 million subscribers at the end of 2016. Self-pay net adds were 1.66 million last year, boosting self-pay subscribers to almost 26 million at the end of the year. Adjusted EBITDA rose 20% year over year in the fourth quarter, reaching $475 million. Average revenue per use ticked upward 3% to $12.91.

For 2017, Sirius XM expects about 1.3 million self-pay net subscriber adds and about $5.3 billion in revenue. The company looks for about $2.025 billion in adjusted EBITDA.

Shares of the company rose by as much as 0.84% to $4.81 in premarket trades this morning.

Merck’s animal health sales beat estimates

Merck’s GAAP earnings per share rose to 42 cents from 35 cents per share a year ago. Pharmaceutical sales fell 1% year over year to $8.9 billion in the fourth quarter. Animal health revenue, however, rose 6% to $884 million, beating the consensus of $867 million.

Singulair sales declined 23% to $210 million, while Januvia and Janumet sales ticked upward 4% to $1.5 billion. Keytruda sales surged 125% to $483 million. Gardasil sales rose 9% year over year to $542 million. Remicade sales fell 32% to $269 million.

Merck expects this year’s adjusted earnings to come in between $3.72 and $3.87 per share. The consensus currently stands at $3.83 per share. The Drug maker expects full-year revenue for this year to be between $38.6 billion and $40.1 billion, against the consensus of $40.1 billion.

Shares of the drug maker rose by as much as 1.03% to $62.74 in premarket trades this morning.